Immunotherapies in the form of monoclonal antibodies specifically binding to HER-2 receptor, added to chemotherapy, are the cornerstone for HER-2-overexpressing BC therapy and have led to significant improvements in HER2-positive BC prognosis compared to previous chemotherapy regimens. Here, ERBB2 is linked to breast cancer.